Charles Schwab Investment Management Inc Lineage Cell Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 68,275 shares of LCTX stock, worth $84,661. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,275
Previous 503,193
86.43%
Holding current value
$84,661
Previous $226,000
72.57%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding LCTX
# of Institutions
142Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$61.5 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$11.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$10.5 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$8.41 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$6.69 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $210M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...